CYBA (Gene)

Organism:

Homo sapiens

Synonyms:CGD4, CYBA, ENTREZ:1535, HGNC:2577, MIM:608508, NM_000101, NP_000092, XM_011522905, XP_011521207, cytochrome b-245 alpha chain, p22-PHOX

Omim:OMIM:608508

Id:ENSG00000051523

Hgnc:HGNC:2577

Entrez:1535

Ensembl:ENSG00000051523

Description:cytochrome b-245 alpha chain

Cytochrome b is comprised of a light chain (alpha) and a heavy chain (beta). This gene encodes the light, alpha subunit which has been proposed as a primary component of the microbicidal oxidase system of phagocytes. Mutations in this gene are associated with autosomal recessive chronic granulomatous disease (CGD), that is characterized by the failure of activated phagocytes to generate superoxide, which is important for the microbicidal activity of these cells. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CYBA's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CYBA.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CYBA.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CYBA.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CYBA.

Results found

Linked to

	Label	Description
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE120612 4 V 1 ETOPOSIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 8 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE145195 PPP2R3B overexpression 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 4 PALMITIC ACID HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE120612 4 V 1 ETOPOSIDE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 sulforaphane 8 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE145195 PPP2R3B overexpression 0 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 4 PALMITIC ACID HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.